Navigation Links
GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
Date:11/15/2007

p>

of these four trials evaluated a low dose (1/10th of the vaccine dose)

vaccination program. Preliminary results from this blinded trial

demonstrated excellent vaccine safety and positive anti-HIV-1 immune

responses to the vaccine in 9 of 11 participants where 9 people

received GeoVax HIV/AIDS vaccines and 2 received placebos. All trial

participants were normal, healthy individuals. Final results will be

compiled for later public release. The 2nd of four trials, initiated

September 2006, is designed to evaluate results from full dose

administration of GeoVax HIV/AIDS vaccines. Recent data indicates

excellent safety in this full dose trial with immune response data from

the majority of vaccine recipients.

-- In June and July, GeoVax announced it engaged Althea Technologies,

Inc., and BioReliance Corporation, as contract manufacturers for its

HIV-1 DNA and HIV-1 MVA (AIDS) vaccines. These vaccines will be

utilized in GeoVax's advanced Phase 2 clinical trials planned for early

2008. GeoVax HIV/AIDS vaccines are designed to prevent development of

Acquired Immunodeficiency Disease (AIDS) caused by the virus known as

HIV-1 by vaccinating individuals prior to AIDS virus infection. The

vaccine regimen employs a two-vaccine "prime-boost strategy." Trial

participants will be administered GeoVax HIV-1 DNA vaccine which

"primes" the immune system followed by GeoVax's HIV-1 MVA (Modified

Vaccinia Virus) boost. Both vaccines deliver over 50% of the AIDS virus

components but cannot cause AIDS. Safety and immunological results

from earlier as well as ongoing human trials are very encouraging thus

supporting planned acceleration of large scale Phase 2 clinical

studies.

-- In September, GeoVax announced receipt of an estimated $15,000,000

In
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. Biopure Announces 2007 Third Quarter Financial Results
5. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
6. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
7. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
8. QIAGEN N.V. (Nasdaq: QGEN) Invites You to Join Its Third Quarter 2007 Earnings Conference Call on the Web
9. Pharmacopeia Announces Third Quarter 2007 Financial Results
10. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
11. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)... THOUSAND OAKS, Calif., July 30, 2015  Amgen ... for the second quarter of 2015. Key results ... versus the second quarter of 2014 to $5,370 ... primarily by Enbrel ® (etanercept), Prolia ® ... (carfilzomib) and XGEVA ® (denosumab). Unfavorable ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
Breaking Medicine Technology:Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... , NATICK, Mass., Dec. 10 Boston Scientific Corporation (NYSE: ... of $2 billion aggregate principal amount of its senior notes under ... $850 million of 4.50 percent notes due January 2015, $850 million ... 7.375 percent notes due January 2040. The Company expects the ...
... , SAN ANTONIO, Dec. 10 Genomic ... The Lancet Oncology published positive results from a study ... estrogen receptor-positive breast cancer conducted by the Southwest Oncology Group ... The Lancet Oncology published these results ...
Cached Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... to clarify, edit and delete any message including ones already sent. , While text ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... Times magazine. What are the STASH awards? The Significant Technological Achievements in ... the cannabis-cultivation community as well as tried-and-true products that have stood the test ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... When the ... stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia . ... in process. , To commemorate introduction of this new type of sod, Super-Sod is ...
(Date:7/31/2015)... ... 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, ... is the Super Bowl. In the two weeks that separate the conference championships and the ... 2016 Super Bowl game will mark the 50th time it has been held and the ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2
... , , ... first roundtable of Health and Tourism ministerial delegates came ... the steps required to give it the necessary thrust. ... the high-powered congregation of senior ministers and policy makers ...
... unclear , WEDNESDAY, Dec. 2 (HealthDay News) -- New ... germs, including bacteria that cause respiratory disease. , But as ... of the new study aren,t sure what, if any, hazard ... Microbes surround us every day of our lives. , ...
... not be able to tell a good book by its ... old book by its smell. In a report in ACS, ... of a new test that can measure the degradation of ... The nondestructive "sniff" test could help libraries and museums preserve ...
... Dec. 2 Holly Potter, vice president, Public Relations, National ... Team Leader" award at PR News, PR People ... PR News, PR People Awards competition showcases the ... are making communications matter in the marketplace. The winners of ...
... , Media Advisory for Thursday, Dec. ... to Speak at Luncheon Meeting of Army Wounded Warriors; Army ... , WASHINGTON, Dec. 2 The following was released today ... Wounded veterans and career counselors from the Army Wounded Warrior ...
... could be linked to life span in males , WEDNESDAY, ... span in humans and other mammals and could help explain ... say. , The researchers found that mice created using two ... 186 days longer than mice created from the normal combination ...
Cached Medicine News:Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3Health News:Smokers Inhaling Germs With Each Cigarette 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 2Health News:Kaiser Permanente Public Relations Leader Wins PR People Award 3Health News:Wounded Vets, CAREER Counselors Gather in Washington as Obama Announces Afghanistan Troop Buildup 2Health News:Sperm Gene May Cause Men's Longevity Disadvantage 2
... surgeon and O.R. staff work hard to ... fluid intravasation. Manual methods are complicated, time-consuming, ... DOLPHIN II Fluid Management System for hysteroscopy, ... endoscopic irrigation. It has been developed to ...
... These 3mL PYREX volumetric pipets ... tolerances in accordance with ASTM ... pipet is individually serialized and ... Identification and Capacity, traceable to ...
... 4mL PYREX volumetric pipets are ... (TC - bottom line) and ... line) to specifications for Class ... color-coded with colored graduations and ...
1000L...
Medicine Products: